Biotech Values

[exwannabe]

RE: ADLS and cethromycin

I would certainly wonder why Abbott outlicensed a drug that will compete against it's own Biaxin, and that was after running 6 P3 trials on cethro.

Even if it is approvable in CAP, what is the commercial story? It is going up against a generic w/o any obvious advantage and will carry a 18% net-sales royalty hit.

And there will certainly be more dillution (if they haven't already sold more this year, haven't bothered to go through all the SEC filings). The financials are bleak.

By all means if you feel there is positives that more than outweigh this, post the story.